# Cancer Gene Therapy Market > Cancer Gene Therapy Market Research Report: Size, Share, Trend Analysis By Therapeutic Approach (Gene Editing, Gene Transfer, Oncolytic Virus Therapy, Gene Silencing, Immunotherapy), By Target Disease (Breast Cancer, Lung Cancer, Leukemia, Colorectal Cancer, Prostate Cancer), By Types of Therapy (Ex-Vivo Therapy, In-Vivo Therapy, Combination Therapy), By Delivery Method (Viral Vectors, Plasmid DNA, Nanoparticles) andBy Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 13.37% - **2024:** $ 8.05 Billion - **2025:** $ 9.13 Billion - **2035:** $ 32.01 Billion - **Key Players:** Novartis (CH), Gilead Sciences (US), Bristol-Myers Squibb (US), Amgen(US), Sangamo Therapeutics (US), Bluebird Bio (US), Spark Therapeutics (US), Celyad Oncology (BE), Zymeworks (CA) **Report ID:** MRFR/Pharma/40603-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/cancer-gene-therapy-market-42268 --- ## Market Summary ## **Cancer Gene Therapy Market Overview** As per MRFR analysis, the Cancer Gene Therapy Market Size was estimated at 7.1 (USD Billion) in 2023. The Cancer Gene Therapy Market Industry is expected to grow from 8.05 (USD Billion) in 2024 to 32.0 (USD Billion) by 2035. The Cancer Gene Therapy Market CAGR (growth rate) is expected to be around 13.37% during the forecast period (2025 - 2035). ### **Key Cancer Gene Therapy Market Trends Highlighted** The Global Cancer Gene Therapy Market is witnessing several significant trends driven primarily by advancements in technology and an increased understanding of genetic mechanisms related to cancer. Key market drivers include a growing focus on personalized medicine, as treatments customized to individual genetic profiles are proving more effective. Innovations in gene editing techniques, such as CRISPR and other delivery systems, are making therapies more accessible and easier to administer, enhancing their appeal to both healthcare providers and patients. Furthermore, increased investment from both the public and private sectors supports ongoing research, which drives the development of new gene therapies. In the context of the target market, these clinical trials appear to have promising opportunities, particularly with the ongoing investment by health systems in precision medicine. There is a steady rise in interest in such therapies, which encourages companies to increase their spending on development spending and investment collaboration to devise new methods of administering medicine and improving outcomes for their patients. The expanding diagnosis of cancer through genetic testing provides the chance for the introduction of gene therapies in the adjuvant treatment of cancer. Furthermore, there are newer markets that offer a low-hanging fruit as the healthcare systems upgrade, and there is a wider appetite for innovative therapies. Recently, many practitioners have been blending [gene therapy](../../../reports/gene-therapy-market-8399) with other techniques, such as immunotherapy and chemotherapy. In the context of the target market, these clinical trials appear to have promising opportunities, particularly with the ongoing investment by health systems in precision medicine. There is a steady rise in interest in such therapies, which encourages companies to increase their spending on development spending and investment collaboration to devise new methods of administering medicine and improving outcomes for their patients. The expanding diagnosis of cancer through genetic testing provides the chance for the introduction of gene therapies in the adjuvant treatment of cancer. Furthermore, there are newer markets that offer a low-hanging fruit as the healthcare systems upgrade, and there is a wider appetite for innovative therapies. Recently, many practitioners have been blending gene therapy with other techniques, such as immunotherapy and chemotherapy. This combination approach aims to improve efficacy and reduce the risk of resistance, making treatment transitions smoother for patients. Regulatory bodies are also increasingly supportive, expediting approval processes for innovative therapies. These collaborative efforts and technological advancements are likely to transform the landscape of cancer treatment, ultimately improving survival rates and quality of life for patients diagnosed with cancer. As the market evolves, continued innovation and collaboration will be essential to harness the full potential of gene therapy in the fight against cancer. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Cancer Gene Therapy Market Drivers** ### Increasing Investment in Cancer Research The Global Cancer Gene Therapy Market Industry is witnessing a significant increase in investment dedicated to cancer research. Government agencies, private organizations, and non-profit entities are funneling substantial resources into the development of innovative cancer therapies, including gene therapy. This momentum reflects a larger trend focused on addressing the pressing need for effective cancer treatments, especially given the rising global cancer prevalence .With projected market valuation growth that anticipates reaching billions in the coming years, these investments are key to advancing research and technology, ultimately resulting in successful gene therapy treatments designed to combat various types of cancers. A robust infrastructure supporting research institutions and clinical trials is necessary to expedite the path from laboratory discoveries to actual therapies, thus bridging the gap between theoretical potential and real-world applications. Additionally, collaborations between biotech firms and academic institutions are multiplying, leading to enhanced knowledge sharing and accelerated product development in the Global Cancer Gene Therapy Market. This team effort bolsters innovation and hastens the clinical application of breakthroughs. With ongoing collaborations, the dream of personalized gene therapies tailored to individual patients based on their genetic makeup becomes increasingly feasible. The funding is not limited to the research phase alone; it also supports clinical trials, regulatory approvals, and scalability of these therapies to ensure that they reach the patients who need them the most. Consequently, this investment climate is positively influencing the Global Cancer Gene Therapy Market and is likely to drive forward its growth trajectory significantly over the next several years. ### Technological Advancements in Gene Therapy Technological innovations are a primary driver propelling the Global Cancer Gene Therapy Market Industry. Recent advancements in genetic engineering techniques, such as CRISPR-Cas9 and other gene editing technologies, have revolutionized how cancer therapies are developed. These technologies enable precise modifications to genetic material, allowing for targeted treatments that are more effective and less harmful compared to traditional therapies.As these advancements continue to evolve, they enhance the safety and efficacy of gene therapies, leading to a more robust pipeline of products poised to enter the market. Furthermore, the ability to design and manufacture viral vectors that deliver the therapeutic genes optimally is improving consistently, facilitating more successful treatments. ### Growing Awareness and Acceptance of Gene Therapy In recent years, there has been a marked increase in awareness and acceptance of gene therapies among healthcare professionals and the general public. Educational campaigns highlighting the benefits, safety, and effectiveness of gene therapies are helping to foster a climate of trust and optimism among patients who previously may have been hesitant to explore these options. As more success stories emerge, alongside the expansion of evidence supporting gene therapy, the stigma associated with novel treatment modalities diminishes.This growing acceptance is crucial for driving demand in the Global Cancer Gene Therapy Market Industry, encouraging more patients to seek out these next-generation therapies. ## **Cancer Gene Therapy Market Segment Insights** ### **Cancer Gene Therapy Market Therapeutic Approach Insights** The Global Cancer Gene Therapy Market is experiencing robust growth, driven significantly by various therapeutic approaches designed to target and treat cancer at its genetic roots. The market is projected to reach a valuation of 8.05 USD Billion by 2024, reflecting the increasing investment in advanced oncology solutions. Among the different therapeutic approaches, Gene Editing holds a notable position with a market valuation of 1.5 USD Billion in 2024 and is expected to rise to 6.0 USD Billion by 2035, showcasing its potential to dominate the market due to its precision and effectiveness in altering disease-causing genes. Gene Transfer is another important approach in this segment, valued at 2.0 USD Billion in 2024 and projected to grow to 8.0 USD Billion by 2035, highlighting its capability to introduce healthy genes into patients' cells, thus addressing genetic disorders that lead to cancer. Oncolytic Virus Therapy also contributes significantly to market growth, with a valuation of 1.2 USD Billion in 2024 and an expected increase to 5.0 USD Billion by 2035, as it utilizes genetically engineered viruses to selectively infect and destroy cancer cells, presenting a novel strategy for cancer treatment. Additionally, Gene Silencing, with a valuation of 1.35 USD Billion in 2024, is anticipated to grow to 5.5 USD Billion by 2035, offering hope through the suppression of specific gene expression that fuels tumor growth. Lastly, Immunotherapy, valued at 2.0 USD Billion in 2024 and expected to reach 7.5 USD Billion by 2035, plays a crucial role in leveraging the body's immune system to combat cancer, making it one of the most exciting areas in cancer treatment. The Overall segmentation of the Global Cancer Gene Therapy Market showcases diverse avenues of innovation, where advancements in Molecular Biology and Genetic Engineering are paving the way for tailored treatments. This not only enhances treatment efficacy but also provides new avenues for clinical applications, driving the market's trajectory as it evolves to meet the needs of patients worldwide. With continuous research and improvement of these therapeutic approaches, the Global Cancer Gene Therapy Market is set for substantial expansion, thanks to initiatives aimed at overcoming challenges in traditional cancer therapies and targeting the genetic basis of malignancies directly. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Cancer Gene Therapy Market Target Disease Insights** The Global Cancer Gene Therapy Market is poised for substantial growth, with a projected valuation of 8.05 USD Billion in 2024. The drive behind this growth is largely due to a rise in cancer prevalence, alongside the development of advanced therapeutic techniques aimed at specific diseases. Among various target diseases, Breast Cancer and Lung Cancer persist as key areas, accounting for a significant portion of the market. Breast Cancer, known for its high occurrence rates, demands targeted therapies, reflecting a crucial focus for cancer gene therapy innovations.Lung Cancer is similarly critical, given its high mortality rate and pressing need for effective treatment options. Leukemia also plays a notable role as research continues to uncover genetic mutations that can be targeted therapeutically. Colorectal Cancer is noteworthy due to its increasing incidence globally, further emphasizing the need for effective gene therapies. Prostate Cancer, while common in males, showcases the importance of precision medicine. Overall, the Global Cancer Gene Therapy Market data demonstrates substantial potential fueled by a focus on targeted disease treatment alongside trends that emphasize personalized therapies and genetic insights to tackle various cancer forms effectively. ### **Cancer Gene Therapy Market Type of Therapy Insights** The Global Cancer Gene Therapy Market is poised for substantial growth, with a projected market value of 8.05 billion USD in 2024. This segment is predominantly characterized by various types of therapy, among which Ex-Vivo Therapy and In-Vivo Therapy play pivotal roles. Ex-Vivo Therapy, which involves modifying the patient's cells outside the body and then reintroducing them, is experiencing strong adoption due to its targeted approach and efficacy in personalized treatments. In-Vivo Therapy, on the other hand, involves direct delivery of therapeutic genes into the patient's body, which is significant for its ability to offer real-time treatment, making it a dominant choice in scenarios requiring immediate intervention.Furthermore, Combination Therapy leverages multiple treatment modalities and showcases the trend toward integrative approaches for enhanced effectiveness against cancer. The market growth is driven by rising incidences of cancer, advancements in genomic technologies, and increased investment in research and development. However, challenges like regulatory hurdles and high treatment costs can impede progress. Overall, the opportunistic landscape continues to evolve, shaped by innovations in the Global Cancer Gene Therapy Market revenue, segmentation, and industry standards. ### **Cancer Gene Therapy Market Delivery Method Insights** The Global Cancer Gene Therapy Market, particularly in the Delivery Method segment, has been gaining attention, with a projected market value of 8.05 billion USD in 2024 and an increase to 32.0 billion USD by 2035. This segment plays a crucial role in the effective delivery of therapeutic genes to targeted cancer cells. Among the various methods, viral vectors have been at the forefront, providing efficient gene transfer capabilities due to their natural ability to infect cells. Plasmid DNA is also significant as it offers a simpler production process and greater safety profiles, making it popular for therapeutic applications. Nanoparticles are emerging rapidly as they facilitate controlled and targeted delivery, potentially enhancing therapeutic outcomes while minimizing side effects. Overall, the interplay between these delivery methods is crucial for the successful application of gene therapies in oncology, addressing the growing need for effective treatment options. The Global Cancer Gene Therapy Market data shows not only robust growth but also an evolving landscape of delivery technologies that promise improved patient outcomes. Market trends underscore the importance of this segment in the overall market landscape, with each method contributing unique advantages that cater to specific therapeutic requirements and challenges.. ### **Cancer Gene Therapy Market Regional Insights** The Regional segmentation of the Global Cancer Gene Therapy Market reveals significant insights into its valuation and growth dynamics among various regions. In 2024, North America is set to dominate the market, valued at 3.5 USD Billion, contributing to the larger market growth driven by advanced healthcare infrastructure and high research investment. Europe follows with a market valuation of 2.5 USD Billion, exemplifying substantial growth due to increased awareness and adoption of gene therapies. Meanwhile, the APAC region stands at 1.8 USD Billion in 2024, showcasing its potential driven by a rising patient population and improved healthcare facilities.In South America, the market is valued at 0.8 USD Billion, which reflects emerging opportunities despite challenges such as regulatory barriers. Lastly, the MEA region is estimated at 0.45 USD Billion, indicating a nascent yet developing landscape with significant growth potential as investments in healthcare increase. Collectively, these regions offer an insightful overview of the Global Cancer Gene Therapy Market revenue, revealing distinct factors contributing to their growth and the overall dynamic of the market. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Cancer Gene Therapy Market Key Players and Competitive Insights** The Global Cancer Gene Therapy Market is an evolving and highly competitive landscape that is characterized by rapid advancements in technology and treatment methodologies. This market has garnered significant attention from pharmaceutical companies, biotech firms, and research institutions worldwide, as the innovative approach of utilizing gene therapy to treat cancer presents a transformative opportunity to enhance patient outcomes. Various players are actively engaging in research and development, leveraging collaborations and partnerships to accelerate product development and clinical trials. As therapies are developed, regulatory considerations, patient accessibility, and pricing strategies also play crucial roles in shaping competitive dynamics within the market.Celgene, a prominent player in the Global Cancer Gene Therapy Market, has established itself through a strong commitment to oncology research and development. The company has cultivated a robust pipeline of innovative therapies aimed at targeting different cancer types, leveraging its experience in the field of hematology and oncology. Celgene's strengths lie in its extensive research capabilities and a well-established network of collaborations that enhance its ability to bring novel therapies to market more efficiently. Additionally, its focus on precision medicine and personalized treatment approaches has positioned Celgene favorably in a market that increasingly prioritizes tailored therapies, demonstrating strength in aligning with current medical trends and patient needs.Sangamo Therapeutics presents another noteworthy competitor in the Global Cancer Gene Therapy Market, known for its pioneering work in gene editing technologies, particularly ZFP-TFs (zinc finger protein transcription factors). This innovative approach allows for precise modifications to genes, which can significantly improve therapeutic efficacy in cancer treatment. Sangamo Therapeutics has a solid emphasis on advancing its proprietary technology, positioning itself as a leader in the development of targeted gene therapies. The company's strength lies in its strong intellectual property portfolio and strategic partnerships that enhance its research capabilities. Furthermore, Sangamo's dedication to addressing unmet medical needs through gene therapy positions it strategically within the market, making it a strong contender amidst the ongoing evolution of cancer treatment paradigms. ### **Key Companies in the Cancer Gene Therapy Market Include** - Celgene - Sangamo Therapeutics - Celyad Oncology - **[Novartis](https://www.novartis.com/news/media-releases/novartis-expands-kymriah-manufacturing-footprint-first-ever-approved-site-commercial-car-t-cell-therapy-manufacturing-asia)** - Zymeworks - Bristol Myers Squibb - Gilead Sciences - Adaptimmune - Medigene - bluebird bio - Legend Biotech - OncoSec Medical - Amgen - Heap Bio - Vir Biotechnology ## Cancer Gene Therapy Market Industry Developments - **Q1 2024: Tecelra® (afamitresgene autoleucel) becomes first TCR-T therapy ever approved by the FDA** Tecelra® (afamitresgene autoleucel), developed by Adaptimmune, received FDA approval as the first TCR-T cell therapy for metastatic or unresectable synovial sarcoma, marking a major milestone in cancer gene therapy. - **Q1 2024: Amtgavi™ (lifileucel) receives FDA approval as first TIL therapy for advanced melanoma** Amtgavi™ (lifileucel), developed by Iovance Biotherapeutics, was approved by the FDA as the first tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma, and is the first one-time individualized and unmodified T cell therapy approved for a solid tumor cancer. - **Q1 2025: AUCATZYL (obecabtagene autoleucel) approved by FDA** AUCATZYL (obecabtagene autoleucel), developed by Autolus Limited, received FDA approval in 2025, expanding the portfolio of gene therapies available for cancer treatment. - **Q1 2025: BEQVEZ (fidanacogene elaparvovec-dzkt) receives FDA approval** BEQVEZ (fidanacogene elaparvovec-dzkt), developed by Pfizer, was approved by the FDA in 2025, representing a new gene therapy option in the oncology space. - **Q1 2025: CARVYKTI (ciltacabtagene autoleucel) receives FDA approval** CARVYKTI (ciltacabtagene autoleucel), developed by Janssen Biotech, Inc., was approved by the FDA in 2025, further advancing gene therapy options for cancer patients. - **Q1 2025: ABECMA (idecabtagene vicleucel) receives FDA approval** ABECMA (idecabtagene vicleucel), developed by Celgene Corporation, a Bristol-Myers Squibb Company, was approved by the FDA in 2025, adding to the growing list of gene therapies for cancer. - **Q1 2025: ADSTILADRIN (nadofaragene firadenovec-vcng) receives FDA approval** ADSTILADRIN (nadofaragene firadenovec-vcng), developed by Ferring Pharmaceuticals A/S, was approved by the FDA in 2025, contributing to the expansion of gene therapy treatments for cancer. - **Q1 2025: ALLOCORD (HPC, Cord Blood) receives FDA approval** ALLOCORD (HPC, Cord Blood), developed by SSM Cardinal Glennon Children's Medical Center, was approved by the FDA in 2025, supporting the use of gene therapy in oncology. - **Q2 2025: Highlights from ACGT Summit 2025: Cell and Gene Therapy** The ACGT Summit 2025 brought together 90 researchers and leaders from 51 institutions and companies to discuss recent FDA approvals and major breakthroughs in cancer gene therapy, including the first TCR-T and TIL therapies for solid tumors. ## **Cancer Gene Therapy Market Segmentation Insights** ### **Cancer Gene Therapy Market****Therapeutic Approach****Outlook** - Gene Editing - Gene Transfer - Oncolytic Virus Therapy - Gene Silencing - Immunotherapy ### **Cancer Gene Therapy Market****Target Disease****Outlook** - Breast Cancer - Lung Cancer - Leukemia - Colorectal Cancer - Prostate Cancer ### **Cancer Gene Therapy Market****Type of Therapy****Outlook** - Ex-Vivo Therapy - In-Vivo Therapy - Combination Therapy ### **Cancer Gene Therapy Market****Delivery Method****Outlook** - Viral Vectors - Plasmid DNA - Nanoparticles ### **Cancer Gene Therapy Market****Regional****Outlook** - North America - Europe - South America - Asia Pacific - Middle East and Africa ## Market Drivers ### Rising Incidence of Cancer The increasing prevalence of cancer worldwide is a primary driver for the Cancer Gene Therapy Market. According to recent statistics, cancer cases are projected to rise significantly, with estimates suggesting that by 2040, the number of new cancer cases could reach over 27 million annually. This alarming trend necessitates innovative treatment options, including gene therapy, which aims to target the genetic basis of cancer. As healthcare systems grapple with the growing burden of cancer, the demand for effective therapies is likely to escalate, propelling the Cancer Gene Therapy Market forward. Furthermore, the shift towards more personalized treatment approaches aligns with the capabilities of gene therapy, which can be tailored to individual genetic profiles, thereby enhancing treatment efficacy and patient outcomes. ### Increased Investment in Cancer Research The Cancer Gene Therapy Market is experiencing a surge in investment from both public and private sectors. Governments and organizations are recognizing the urgent need for innovative cancer treatments, leading to increased funding for research initiatives. For instance, funding for cancer research has seen a substantial rise, with billions allocated annually to support clinical trials and the development of new therapies. This influx of capital is fostering collaboration among researchers, biotech companies, and academic institutions, which is essential for advancing gene therapy technologies. As more resources are dedicated to understanding cancer at the molecular level, the potential for breakthroughs in gene therapy is likely to expand, further propelling the Cancer Gene Therapy Market. ### Advancements in Gene Editing Technologies Recent advancements in gene editing technologies, such as CRISPR and TALEN, are revolutionizing the Cancer Gene Therapy Market. These technologies enable precise modifications to the genetic material of cancer cells, offering new avenues for treatment. The ability to edit genes with high accuracy has led to the development of novel therapies that can potentially cure previously untreatable cancers. Market data indicates that the gene editing market is expected to grow at a compound annual growth rate of over 30% in the coming years, reflecting the increasing investment in research and development. As these technologies continue to evolve, they are likely to enhance the effectiveness and safety of gene therapies, thereby driving growth in the Cancer Gene Therapy Market. ### Regulatory Support for Gene Therapy Approvals Regulatory bodies are increasingly supportive of gene therapy innovations, which is a crucial driver for the Cancer Gene Therapy Market. Recent regulatory frameworks have been established to expedite the approval process for gene therapies, recognizing their potential to address unmet medical needs in oncology. For example, the introduction of breakthrough therapy designations allows for faster review and approval of promising gene therapies. This regulatory support not only encourages pharmaceutical companies to invest in gene therapy research but also instills confidence in investors and stakeholders. As more gene therapies receive regulatory approval, the market is likely to witness a surge in available treatment options, further stimulating growth in the Cancer Gene Therapy Market. ### Growing Awareness and Acceptance of Gene Therapies There is a notable increase in awareness and acceptance of gene therapies among healthcare professionals and patients, which is positively impacting the Cancer Gene Therapy Market. Educational campaigns and successful case studies are helping to demystify gene therapy, showcasing its potential benefits in treating various cancers. As patients become more informed about their treatment options, they are increasingly advocating for advanced therapies, including gene therapy. Market Research Future indicates that patient acceptance of gene therapies is on the rise, with many expressing willingness to consider these innovative treatments. This shift in perception is likely to drive demand for gene therapy solutions, thereby contributing to the growth of the Cancer Gene Therapy Market. ## Future Outlook The Cancer Gene Therapy Market is projected to grow at a 13.37% CAGR from 2025 to 2035, driven by advancements in technology, increasing prevalence of cancer, and rising investments in research. **New opportunities:** - Development of personalized gene therapies targeting specific cancer mutations. - - Expansion of telehealth services for remote patient monitoring and consultations. - Strategic partnerships with biotech firms for innovative product development. By 2035, the Cancer Gene Therapy Market is expected to be robust, reflecting substantial growth and innovation. ## Segment Insights ### By Therapeutic Approach: Immunotherapy (Largest) vs. Gene Editing (Fastest-Growing) In the Cancer Gene Therapy Market, Immunotherapy dominates with the largest share, driven by its effectiveness in harnessing the body's immune system to target and destroy cancer cells. It is being adopted widely in treatment protocols, reflecting a shift towards personalized medicine. In contrast, Gene Editing, employing tools like CRISPR, is gaining rapid traction as it offers precise modifications at the genetic level, unlocking new potential for curing previously untreatable cancers. As research progresses, its market share is expected to grow significantly. The growth trends in the Cancer Gene Therapy Market are largely influenced by advancements in technology and increased investment in research and development. Immunotherapy continues to thrive due to its robust clinical results and regulatory approvals, while Gene Editing benefits from breakthroughs in genetic research. The increasing prevalence of cancer and a shift towards targeted therapies are propelling demand for these therapeutic approaches, further expanding their market presence. Therapeutic Approaches: Immunotherapy (Dominant) vs. Gene Editing (Emerging) Immunotherapy remains the dominant therapeutic approach in the Cancer Gene Therapy Market, characterized by its ability to leverage the body's immune response to fight tumors effectively. This method includes monoclonal antibodies, checkpoint inhibitors, and CAR T-cell therapy, which have shown promising results in a variety of cancers. In contrast, Gene Editing is emerging as a revolutionary approach, focusing on the precise alteration of genetic material to target cancer at its source. With increasing research and successful trials, this segment is gaining popularity for its potential to provide long-lasting, curative treatments for patients. As technologies evolve, both approaches are expected to co-exist and complement each other, advancing the field of cancer therapy. ### By Target Disease: Breast Cancer (Largest) vs. Lung Cancer (Fastest-Growing) In the Cancer Gene Therapy Market, Breast Cancer represents the largest share among the target diseases, attributed to its high prevalence and considerable research investment. This segment benefits from increased awareness and improved screening technologies, fostering robust growth. Conversely, Lung Cancer has emerged as the fastest-growing segment, driven by heightened incidence rates and the ongoing demand for innovative therapies that address the unique genomic characteristics of this disease. Target Disease: Breast Cancer (Dominant) vs. Lung Cancer (Emerging) Breast Cancer gene therapy has dominated the market due to significant advancements in targeted therapies and the increasing number of clinical trials. This segment is characterized by a wide range of treatment options tailored to specific genetic mutations, making it a focal point for researchers and clinicians alike. Meanwhile, Lung Cancer is recognized as an emerging sector within the market, with rapid developments in immunotherapy and personalized medicine leading the way. The rising prevalence of smoking and environmental factors heightens the necessity for innovations in treatment, positioning lung cancer therapies as a vital growing category in the Cancer Gene Therapy Market landscape. ### By Type of Therapy: Ex-Vivo Therapy (Largest) vs. In-Vivo Therapy (Fastest-Growing) In the Cancer Gene Therapy Market, the type of therapy segment is primarily dominated by Ex-Vivo Therapy, which holds the largest share due to its established methods and effectiveness in providing targeted treatments. In-Vivo Therapy, while smaller in current share, is rapidly gaining traction as advancements in technology and delivery systems improve its appeal. Combination Therapy, though significant, serves more of a supplementary role in this landscape, integrating both ex-vivo and in-vivo methods to enhance treatment efficacy. The growth trends within this segment showcase a clear shift toward In-Vivo Therapy as it becomes the focal point of research and development efforts. Factors driving this growth include improved patient outcomes and the ability to deliver treatment directly to affected areas within the body. Additionally, ongoing innovations in genetic engineering and vector technology continue to pave the way for expedited development cycles and increased acceptance within the oncology community. Therapy Approach: Ex-Vivo Therapy (Dominant) vs. Combination Therapy (Emerging) Ex-Vivo Therapy stands as the dominant approach within the Cancer Gene Therapy Market, primarily due to its established protocols and success in clinical settings. This therapy entails the modification of a patient's cells outside the body before reintroducing them, allowing for precise targeting and minimal off-target effects. Combination Therapy, emerging in popularity, seeks to integrate multiple therapeutic strategies, including both gene therapies and traditional chemotherapy or immunotherapy. This approach aims to enhance overall treatment efficacy by addressing cancer from various fronts. The combination of ex-vivo techniques with complementary therapies not only demonstrates potential for improved patient outcomes but also reflects a growing trend in personalized medicine, where tailored treatment plans are developed based on individual patient profiles. ### By Delivery Method: Viral Vectors (Largest) vs. Nanoparticles (Fastest-Growing) In the Cancer Gene Therapy Market, the delivery method segment is primarily dominated by viral vectors, which significantly outperform other methods in terms of market share. This is largely attributed to their efficacy in delivering therapeutic genes directly into target cells. Plasmid DNA is also utilized but retains a smaller share, while nanoparticles have emerged recently, capturing attention due to their potential in targeting and minimizing off-target effects, which is crucial in cancer therapy. Delivery Method: Viral Vectors (Dominant) vs. Nanoparticles (Emerging) Viral vectors are the dominant delivery method in the Cancer Gene Therapy Market, renowned for their high transfection efficiency and ability to integrate genetic material into host cells, leading to durable therapeutic effects. They include adenoviruses, lentiviruses, and adeno-associated viruses, each offering unique advantages for different types of cancer. On the other hand, nanoparticles present an emerging alternative, characterized by their versatile composition and ability to encapsulate therapeutic agents for controlled release. This method is gaining traction due to advancements in nanotechnology, making it a promising approach for targeted therapy, especially in overcoming challenges associated with traditional delivery methods. ## Regional Market Share Analysis The Regional segmentation of the Global Cancer Gene Therapy Market reveals significant insights into its valuation and growth dynamics among various regions. In 2024, North America is set to dominate the market, valued at 3.5 USD Billion, contributing to the larger market growth driven by advanced healthcare infrastructure and high research investment. Europe follows with a market valuation of 2.5 USD Billion, exemplifying substantial growth due to increased awareness and adoption of gene therapies. Meanwhile, the APAC region stands at 1.8 USD Billion in 2024, showcasing its potential driven by a rising patient population and improved healthcare facilities.In South America, the market is valued at 0.8 USD Billion, which reflects emerging opportunities despite challenges such as regulatory barriers. Lastly, the MEA region is estimated at 0.45 USD Billion, indicating a nascent yet developing landscape with significant growth potential as investments in healthcare increase. Collectively, these regions offer an insightful overview of the Global Cancer Gene Therapy Market revenue, revealing distinct factors contributing to their growth and the overall dynamic of the market. ## Competitive Benchmarking The Global Cancer Gene Therapy Market is an evolving and highly competitive landscape that is characterized by rapid advancements in technology and treatment methodologies. This market has garnered significant attention from pharmaceutical companies, biotech firms, and research institutions worldwide, as the innovative approach of utilizing gene therapy to treat cancer presents a transformative opportunity to enhance patient outcomes. Various players are actively engaging in research and development, leveraging collaborations and partnerships to accelerate product development and clinical trials.As therapies are developed, regulatory considerations, patient accessibility, and pricing strategies also play crucial roles in shaping competitive dynamics within the market.Celgene, a prominent player in the Global Cancer Gene Therapy Market, has established itself through a strong commitment to oncology research and development.The company has cultivated a robust pipeline of innovative therapies aimed at targeting different cancer types, leveraging its experience in the field of hematology and oncology. Celgene's strengths lie in its extensive research capabilities and a well-established network of collaborations that enhance its ability to bring novel therapies to market more efficiently.Additionally, its focus on precision medicine and personalized treatment approaches has positioned Celgene favorably in a market that increasingly prioritizes tailored therapies, demonstrating strength in aligning with current medical trends and patient needs.Sangamo Therapeutics presents another noteworthy competitor in the Global Cancer Gene Therapy Market, known for its pioneering work in gene editing technologies, particularly ZFP-TFs (zinc finger protein transcription factors).This innovative approach allows for precise modifications to genes, which can significantly improve therapeutic efficacy in cancer treatment. Sangamo Therapeutics has a solid emphasis on advancing its proprietary technology, positioning itself as a leader in the development of targeted gene therapies. The company's strength lies in its strong intellectual property portfolio and strategic partnerships that enhance its research capabilities. Furthermore, Sangamo's dedication to addressing unmet medical needs through gene therapy positions it strategically within the market, making it a strong contender amidst the ongoing evolution of cancer treatment paradigms. ## Recent News & Developments - **Q1 2024: Tecelra® (afamitresgene autoleucel) becomes first TCR-T therapy ever approved by the FDA** Tecelra® (afamitresgene autoleucel), developed by Adaptimmune, received FDA approval as the first TCR-T cell therapy for metastatic or unresectable synovial sarcoma, marking a major milestone in cancer gene therapy. - **Q1 2024: Amtgavi™ (lifileucel) receives FDA approval as first TIL therapy for advanced melanoma** Amtgavi™ (lifileucel), developed by Iovance Biotherapeutics, was approved by the FDA as the first tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma, and is the first one-time individualized and unmodified T cell therapy approved for a solid tumor cancer. - **Q1 2025: AUCATZYL (obecabtagene autoleucel) approved by FDA** AUCATZYL (obecabtagene autoleucel), developed by Autolus Limited, received FDA approval in 2025, expanding the portfolio of gene therapies available for cancer treatment. - **Q1 2025: BEQVEZ (fidanacogene elaparvovec-dzkt) receives FDA approval** BEQVEZ (fidanacogene elaparvovec-dzkt), developed by Pfizer, was approved by the FDA in 2025, representing a new gene therapy option in the oncology space. - **Q1 2025: CARVYKTI (ciltacabtagene autoleucel) receives FDA approval** CARVYKTI (ciltacabtagene autoleucel), developed by Janssen Biotech, Inc., was approved by the FDA in 2025, further advancing gene therapy options for cancer patients. - **Q1 2025: ABECMA (idecabtagene vicleucel) receives FDA approval** ABECMA (idecabtagene vicleucel), developed by Celgene Corporation, a Bristol-Myers Squibb Company, was approved by the FDA in 2025, adding to the growing list of gene therapies for cancer. - **Q1 2025: ADSTILADRIN (nadofaragene firadenovec-vcng) receives FDA approval** ADSTILADRIN (nadofaragene firadenovec-vcng), developed by Ferring Pharmaceuticals A/S, was approved by the FDA in 2025, contributing to the expansion of gene therapy treatments for cancer. - **Q1 2025: ALLOCORD (HPC, Cord Blood) receives FDA approval** ALLOCORD (HPC, Cord Blood), developed by SSM Cardinal Glennon Children's Medical Center, was approved by the FDA in 2025, supporting the use of gene therapy in oncology. - **Q2 2025: Highlights from ACGT Summit 2025: Cell and Gene Therapy** The ACGT Summit 2025 brought together 90 researchers and leaders from 51 institutions and companies to discuss recent FDA approvals and major breakthroughs in cancer gene therapy, including the first TCR-T and TIL therapies for solid tumors. ## Report Scope | MARKET SIZE 2024 | 8.05(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 9.126(USD Billion) | | MARKET SIZE 2035 | 32.01(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 13.37% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Novartis (CH), Gilead Sciences (US), Bristol-Myers Squibb (US), Amgen (US), Sangamo Therapeutics (US), Bluebird Bio (US), Spark Therapeutics (US), Celyad Oncology (BE), Zymeworks (CA) | | Segments Covered | Therapeutic Approach, Target Disease, Types of Therapy, Delivery Method, Regional | | Key Market Opportunities | Advancements in personalized medicine and regulatory support enhance prospects in the Cancer Gene Therapy Market. | | Key Market Dynamics | Rising demand for personalized medicine drives innovation and competition in the Cancer Gene Therapy Market. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the current valuation of the Cancer Gene Therapy Market as of 2024?** A: The Cancer Gene Therapy Market was valued at 8.05 USD Billion in 2024. **Q: What is the projected market size for the Cancer Gene Therapy Market by 2035?** A: The market is projected to reach 32.01 USD Billion by 2035. **Q: What is the expected CAGR for the Cancer Gene Therapy Market during the forecast period 2025 - 2035?** A: The expected CAGR for the Cancer Gene Therapy Market during 2025 - 2035 is 13.37%. **Q: Which therapeutic approach segments are expected to show significant growth?** A: The Gene Transfer segment is projected to grow from 2.0 USD Billion to 8.0 USD Billion by 2035. **Q: What are the leading types of therapy in the Cancer Gene Therapy Market?** A: In-Vivo Therapy is anticipated to expand from 3.0 USD Billion to 12.0 USD Billion by 2035. **Q: Which delivery method is expected to dominate the market?** A: Viral Vectors are likely to lead the market, growing from 3.22 USD Billion to 12.8 USD Billion by 2035. **Q: What are the key diseases targeted by cancer gene therapies?** A: Lung Cancer is projected to grow from 1.8 USD Billion to 7.2 USD Billion by 2035. **Q: Who are the major players in the Cancer Gene Therapy Market?** A: Key players include Novartis, Gilead Sciences, and Bristol-Myers Squibb. **Q: What is the growth potential for immunotherapy in the Cancer Gene Therapy Market?** A: Immunotherapy is expected to increase from 2.55 USD Billion to 10.01 USD Billion by 2035. **Q: How does the market for leukemia treatments compare to other cancers?** A: Leukemia treatments are projected to grow from 1.2 USD Billion to 4.8 USD Billion by 2035, indicating a robust market presence. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/cancer-gene-therapy-market-42268*